Insulet Corporation (PODD) — Q2 2026 Earnings Preview

Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus sits at a manageable bar after modest post-Q1 estimate drift, and the biggest swing factor is whether U.S. new customer starts (NCS) rebounded from Q1 seasonality as management guided.

Heading into Q2 2026, Insulet's bar looks achievable: consensus revenue of ~$787M implies ~21% YoY growth, squarely in the middle of the 20–22% total company guidance range issued on May 6. Management explicitly flagged that U.S. NCS momentum that ramped through Q1 had continued into Q2, and the June 3 launch of the second-generation Omnipod 5 algorithm (lower 100 mg/dL target, improved automated-mode retention) alongside the Libre 3 Plus integration provides a tangible catalyst for new patient conversion and prescriber engagement. Estimates have been remarkably stable since the Q1 print — total revenue consensus has drifted only ~$1M lower from the immediate post-earnings baseline, and operating EPS has edged down ~$0.01, suggesting the Street is broadly comfortable with guidance. The stock has recovered from its May 26 medical device correction lows (from ~$142 to ~$167 as of August 4), but remains ~35% below its 6-month high, meaning the multiple has compressed sharply and the stock is not pricing in a heroic beat. The key wildcard is the second medical device correction: management asserted at the ADA investor event in June that field feedback was positive and the issue was not generating ongoing discussion, but any incremental adverse event disclosure or FDA communication could overshadow an otherwise solid print.

KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar across all key metrics, with total revenue and Omnipod WW revenue the primary swing factors. Operating EPS is the secondary lever, with margin trajectory closely watched given the Q1 E&O headwind from pod configuration transitions.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 4, 2026. Q2 2026 guidance midpoints derived from management guidance issued May 6, 2026 Q1 2026 earnings call (Omnipod revenue growth 21–23%; total company revenue growth 20–22%; U.S. Omnipod growth 18–20%; International Omnipod growth 28–30%).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Source: Visible Alpha Consensus and Actuals Data. PODD has beaten consensus on both total revenue and adjusted operating EPS in each of the last 8 quarters, with EPS beats consistently larger than revenue beats — a pattern driven by operating leverage and share repurchase activity. The consistency of the beat-and-raise cadence sets a high implicit bar even when the stated consensus looks achievable.

Guidance & Commentary Evolution

Key Takeaway: Guidance was raised on May 6 and has not been formally revised since. Management tone at the ADA investor event on June 8 was constructive on quality/recall recovery and pipeline momentum, with no incremental negative signals on the business.

Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 revenue consensus has drifted only ~$1M lower from the immediate post-earnings baseline, and FY 2026 revenue has moved ~$4M lower. The lack of meaningful revision activity suggests the Street is broadly comfortable with guidance and not pricing in incremental risk from the medical device correction.

Source: Visible Alpha Consensus and Actuals Data. The near-zero estimate drift since the Q1 print is notable — it suggests the Street has fully digested the guidance raise and the medical device correction, and is not building in incremental conservatism or optimism. This creates a clean setup where the print itself (rather than pre-print estimate movement) will drive the stock reaction.

Stock Performance

Key Takeaway: PODD has outperformed IHI (+10.3% vs. +8.9%) since the Q1 earnings date (May 6), but both have lagged the S&P 500 (+5.1%). The stock's recovery from the May 26 medical device correction lows is encouraging, but the ~35% six-month multiple compression means the stock is not priced for perfection — a clean print with no new quality issues could drive meaningful re-rating.

PODD vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 — Indexed to 100 at May 6, 2026 (Q1 2026 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Sector ETF used: IHI (iShares U.S. Medical Devices ETF) — appropriate for PODD as a pure-play medical device company in the diabetes technology sub-sector.

Performance since Q1 2026 earnings (May 6, 2026 close) through August 4, 2026: PODD +10.3% ($151.28 → $166.82), IHI +8.9% ($49.71 → $54.11), S&P 500 +5.1% ($733.83 → $771.33). Source: Yahoo Finance / Stock Price Data.

Key events during the period: (1) May 26 — Second medical device correction announced: PODD fell sharply from ~$157 to ~$143 over the following days. (2) June 3 — Omnipod 5 algorithm enhancement + Libre 3 Plus integration launched: stock recovered to ~$153. (3) June 8 — ADA investor event: management presented STRIVE data for Omnipod 6 and Evolve feasibility data; stock moved to ~$152. (4) June 25 — Board appointment (Jonathan Mazelsky, former IDEXX CEO): stock at ~$154. The stock has since recovered to ~$167 as of August 4.

Valuation context: NTM EV/EBITDA of 13.5x and NTM P/E of 23.0x represent a ~57% compression in EV/EBITDA and ~60% compression in P/E over the trailing 12 months — the stock has de-rated dramatically. The 6-month EV/EBITDA compression of ~40% (from 22.7x to 13.5x) suggests the market has priced in significant execution risk. A clean Q2 print with no new quality issues could catalyze multiple re-expansion. Source: Stock Performance Decomposition Data.

Peer Commentary in the Last 60 Days

Key Takeaway: Both Abbott (ABT) and Dexcom (DXCM) reported Q2 2026 results in late July and provided forward-looking commentary highly relevant to PODD's Q2 setup. The most important read-through is Dexcom's confirmation of record new patient starts and accelerating Type 2 non-insulin reimbursement expansion — both are structural tailwinds for Omnipod adoption. Abbott's commentary on CGM capacity investment and Type 2 Medicare expansion timing is also constructive for the broader diabetes device ecosystem.

Note on peer selection: Only forward-looking commentary about Q3 2026 trends or post-Q2 2026 dynamics is included below. Q2 2026 results commentary from peers is included only where it provides read-through to PODD's current-quarter (Q2 2026) setup or near-term outlook. Commentary from prior quarters about prior-quarter results has been excluded.

Dexcom (DXCM) — Q2 2026 Earnings Call (July 30, 2026)

Relevance to PODD Q2 2026: HIGH. DXCM is PODD's primary CGM integration partner (Libre 3 Plus integration launched June 3; G7 integration ongoing). DXCM's commentary on new patient starts, Type 2 reimbursement, and international market dynamics provides direct read-through to PODD's Q2 NCS and revenue trends.

• New patient starts at record levels: "Global new customer starts remained in line with our previous record from last quarter, including a sequential uptick in new customer starts in the US." This is a direct positive read-through for PODD's U.S. NCS in Q2, as CGM adoption and insulin pump adoption are highly correlated. Management noted "broad based performance" across T1, T2 intensive basal, and T2 non-insulin segments.
• Type 2 commercial reimbursement now covers 7M+ patients: "As of this summer, we now have coverage for all people with diabetes across the four largest commercial PBMs... This represents reimbursement for more than 7 million people with type two diabetes who are not on insulin." This is a structural tailwind for PODD's Type 2 NCS, as broader CGM coverage among T2 patients expands the addressable pool for Omnipod 5.
• CMS non-insulin T2 coverage decision expected by year-end: "We do expect to hear back from CMS on that decision before the end of this year, with coverage taking effect in the middle of 2027." If CMS expands coverage to T2 non-insulin patients ("roughly half of the type two Non-insulin population being of Medicare age"), this could unlock a massive new patient funnel for PODD's Fully Closed Loop Type 2 system targeting 2028 launch.
• International comps get tougher in H2 2026: "The comps get a little tougher because we had some great access wins in the back half of last year." This is a mild negative read-through for PODD's international growth, which management already guided to moderate from Q1's 45% CC growth to 28–30% in Q2.
• FX headwind of ~$15M to international revenue in H2: DXCM flagged "about a $15 million impact to international revenue in the second half of the year relative to our prior guidance" from FX. PODD guided to ~200bps FX tailwind to international growth in Q2 — the FX environment appears broadly neutral-to-slightly-positive for PODD's international segment.
• G7 15-day conversion on track; Tandem integration now available: "Remain on track to convert nearly 50% of our US customer base to the G7 15 day system by year end." The G7 15-day integration with Tandem Moby is now available for all adult G7 customers. This is relevant for PODD as it confirms the CGM upgrade cycle is active, which typically precedes or accompanies AID system upgrades.

Limitations: DXCM's commentary is specific to CGM adoption and does not directly address insulin pump competitive dynamics. DXCM's strong Q2 results (EPS of $0.70 vs. $0.61 consensus; raised FY guidance) and stock reaction (+12%) may set a high bar for PODD's own print, as investors may expect a similar beat-and-raise.

Abbott (ABT) — Q2 2026 Earnings Call (July 16, 2026)

Relevance to PODD Q2 2026: MODERATE-HIGH. Abbott is PODD's Libre 3 Plus integration partner (launched June 3, 2026 in the U.S.). ABT's commentary on CGM market size, Type 2 reimbursement expansion, and manufacturing capacity investment provides context for the broader diabetes device demand environment.

• CGM market remains massively underpenetrated: "You've got 75 to 80 million people around the world that could realistically be on a CGM and you've only got 15 million so far." This confirms the long-term structural growth opportunity for the entire diabetes technology ecosystem, including PODD's Omnipod platform.
• U.S. Type 2 Medicare reimbursement expansion could come "in the fall": "US type two is a huge opportunity... unlock around 10 million Medicare beneficiaries... accelerate commercial insurance coverage... multibillion dollar opportunity... in the fall." If Medicare expands CGM coverage to T2 patients in fall 2026, this would be a significant catalyst for PODD's Type 2 NCS in H2 2026 and 2027, as CGM adoption typically precedes or accompanies AID system adoption.
• International reimbursement expansion in active discussions across 12+ countries: "We're in active discussions with a dozen or so countries that are either looking to introduce or to expand reimbursement." Broader international CGM reimbursement is a structural tailwind for PODD's international Omnipod 5 expansion, particularly in markets where CGM coverage is a prerequisite for AID reimbursement.
• $1B investment in fifth CGM manufacturing facility: Abbott's commitment to a fifth manufacturing facility signals high conviction in sustained CGM demand growth. This is indirectly positive for PODD, as CGM supply constraints have historically been a bottleneck for AID system adoption.
• Libre Duo (dual glucose/ketone sensor) CE marked; international rollout in fall 2026: Abbott secured CE mark for Libre Duo and plans international rollout in fall 2026, with FDA approval discussions in "very, very advanced final stages." This product innovation keeps Abbott competitive in the CGM space and is relevant for PODD's Libre 3 Plus integration strategy.

Limitations: Abbott's commentary is primarily focused on its FreeStyle Libre CGM system and does not directly address insulin pump competitive dynamics. The timing of Medicare reimbursement expansion ("in the fall") is uncertain and may not benefit PODD's Q2 2026 results, but is a meaningful catalyst for H2 2026 and 2027.

Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the June 3 simultaneous launch of the second-generation Omnipod 5 algorithm and Libre 3 Plus integration — a direct response to the two most-cited competitive weaknesses (algorithm performance and CGM integration breadth). The ADA investor event on June 8 provided additional clinical validation with STRIVE data for Omnipod 6, and management's tone on the medical device correction was notably more confident.

• June 3, 2026 — Second-generation Omnipod 5 algorithm launched (U.S.): New lower target glucose of 100 mg/dL and improved alarm handling to extend time in automated mode. Early data on 79 users showed 2% improvement in time-in-range and 11% increase in time in automated mode (to 95%) for patients previously spending <90% time in automated mode. Implication: Directly addresses the most-cited competitive weakness vs. Tandem and Medtronic; could improve NCS conversion and retention rates in Q2 and beyond.
• June 3, 2026 — Libre 3 Plus integration launched (U.S.): Simultaneous with algorithm launch. Management had guided this would expand the addressable market by hundreds of thousands of current Libre 3 users. Implication: Expands the funnel for new Omnipod 5 starts among existing Libre users; timing within Q2 means some benefit may already be visible in Q2 NCS data.
• June 3, 2026 — Omnipod Discover data insights platform launched: New platform providing algorithm transparency for clinicians, addressing a key concern about what the algorithm is doing. Implication: Supports prescriber confidence and could accelerate prescriber base expansion beyond the 27,000+ HCPs already reached.
• June 8, 2026 — ADA Investor Event: STRIVE data for Omnipod 6 presented: Omnipod 6 showed 4% uplift in time-in-range (73% → 77% for T1 adults), 7% improvement in time-in-tight-range, and 40% reduction in boluses with similar time-in-range in the bolus-optional phase. Omnipod 6 includes over-the-air pod update capability. Implication: Strong clinical data supports the Omnipod 6 launch timeline (2027); over-the-air updates could accelerate future innovation delivery by several months.
• June 8, 2026 — ADA Investor Event: Evolve pivotal study enrollment confirmed: ~300 patients enrolling for the Fully Closed Loop Type 2 system; submission targeted 2027, launch 2028. Evolution 3 feasibility data showed time-in-range improving from 51% to 66% by week 6. Implication: Confirms the 2028 launch timeline for what management believes will be the first truly fully closed-loop system for T2 diabetes — the most significant long-term growth catalyst.
• June 8, 2026 — ADA Investor Event: Medical device correction tone notably more confident: CMO Dr. Trang Ly stated "no one's asked me about it" and "there's been no discussion really since after the first initial days" in the field. Implication: Suggests the correction is not materially impacting prescriber or patient behavior; reduces the risk of a negative NCS surprise in Q2.
• June 25, 2026 — Jonathan Mazelsky appointed to Board of Directors (effective July 1): Former President and CEO of IDEXX Laboratories (2019–2026). Implication: Adds diagnostics/medical device commercial expertise to the board; signals continued governance strengthening.
• July 1, 2026 — Q2 2026 earnings date announced (August 5, 2026): Confirms the reporting timeline. No pre-announcement or guidance update was issued alongside the announcement. Implication: Absence of a pre-announcement is consistent with results tracking in line with or above guidance.
• July 30–31, 2026 — Dexcom Q2 2026 beat-and-raise: DXCM reported EPS of $0.70 vs. $0.61 consensus; raised FY guidance; stock +12%. Implication: Positive read-through for diabetes device demand broadly; sets a high bar for PODD's own print in terms of investor expectations.

Insider Transaction Activity

Key Takeaway: Insider activity since Q1 earnings is limited to routine director transactions on June 3 — one open-market sale and two open-market purchases by directors, all on the same day. The purchases are modestly encouraging, but the amounts are small and the transactions appear to be routine annual director compensation-related activity. No executive-level open-market buys or unusual sale activity stands out.

Source: SEC Form 4 Filings. All three transactions occurred on June 3, 2026 — the same day as the Omnipod 5 algorithm and Libre 3 Plus integration launch. The clustering of director purchases on a major product launch day is consistent with routine annual director compensation activity rather than a discretionary signal. No executive-level (CEO, CFO, CCO) open-market transactions were filed in the period. The absence of executive selling is a mild positive signal given the stock's recovery from correction lows.